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n Myocardial Infarction Risk Index in
on–ST-Segment Elevation Myocardial Infarction
valuation of Patients in the National Registry of Myocardial Infarction
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lliott M. Antman, MD, FACC,*† Eugene Braunwald, MD, MACC*†
oston, Massachusetts; and Seattle, Washington
OBJECTIVES The purpose of this research was to evaluate the Thrombolysis In Myocardial Infarction risk
index (TRI) to characterize the risk of death among patients with non–ST-segment elevation
myocardial infarction (NSTEMI).
BACKGROUND The TRI, calculated from baseline age, systolic pressure, and heart rate, was established in
patients with ST-segment elevation myocardial infarction (STEMI) and is predictive of
mortality. Patients presenting with NSTEMI are increasing compared to STEMI and
constitute a group with varied risk.
METHODS The TRI was calculated in 337,192 patients from the National Registry of Myocardial
Infarction with NSTEMI. Values and outcomes were compared with 153,486 patients with
STEMI classified by reperfusion status. Comparisons of baseline characteristics and clinical
outcomes stratified by TRI were made.
RESULTS There was a graded relationship between the TRI and mortality in patients with NSTEMI
with a30-fold difference in mortality rates between lowest and highest deciles (p 0.0001).
The index showed good discrimination (c  0.73). Overall mortality in the group with
NSTEMI was higher (10.9%) than patients with STEMI treated with (6.6%) but lower than
for STEMI patients not receiving reperfusion therapy (18.7%). The higher risk in comparison
to patients with STEMI treated with reperfusion therapy was explained largely by the
higher-risk profile of the population with NSTEMI.
CONCLUSIONS There is a graded relationship between TRI and mortality in patients with NSTEMI. This
simple risk index provides important information about mortality in patients across the
spectrum of myocardial infarction, STEMI and NSTEMI. Early identification of NSTEMI
patients who are at high risk of in-hospital mortality may provide clinicians with important
information for initial triage and treatment. (J Am Coll Cardiol 2006;47:1553–8) © 2006
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.075by the American College of Cardiology Foundation
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The Thrombolysis In Myocardial Infarction risk index
TRI) is a simple metric using baseline age, systolic blood
ressure, and heart rate to predict early mortality in patients
ith myocardial infarction (MI) (1). It was derived from
nd validated in clinical trials of patients with ST-segment
levation myocardial infarction (STEMI) (1). In this pop-
lation the TRI maintained much of the predictive value of
ore complex risk scores (2–8) that typically include data
btained during the course of the in-hospital evaluation
ncluding laboratory testing. The TRI was subsequently
hown to be associated with mortality in an unselected
opulation of patients with STEMI from the National
egistry of Myocardial Infarction (NRMI) (9). The value of
he TRI in predicting early mortality among patients with
on–ST-segment elevation myocardial infarction
NSTEMI) is not known (10).
The proportion of patients with acute MI who present
ithout ST-segment elevation continues to rise progres-
From the *TIMI Study Group and †Cardiovascular Division, Brigham and
omen’s Hospital, Boston, Massachusetts; and ‡Ovation Research Group, Seattle,
ashington. The InTIME-II trial was supported by Bristol-Myers-Squibb; Genen-
ech supported NRMI.e
Manuscript received September 23, 2005; revised manuscript received November
1, 2005, accepted November 20, 2005.ively (11). The overall population of patients with STEMI
re generally considered as being at higher risk of early
ortality compared to patients with NSTEMI (12–14).
his early hazard with STEMI has been attributed to fatal
rrhythmias, pump failure, and mechanical complications,
hich are considered to be less frequent in NSTEMI. In
sual clinical practice, perhaps owing to the perceived lower
hort-term risk, patients with NSTEMI are less likely to be
ared for by cardiologists or in a coronary care unit (15), and
re also less likely to be treated with proven therapies such
s aspirin, beta-blockers, and lipid-lowering therapy
11,16,17).
In part as a result of these disparities in management
etween STEMI and NSTEMI, we sought to evaluate the
erformance of the TRI for identifying patients with
STEMI who are at significant risk for in-hospital mor-
ality. An additional goal was to employ the index to charac-
erize differences between patients presenting with these two
orms of MI (18).
ETHODS
he National Registry of Myocardial Infarction, described
lsewhere (19,20), is an observational study of demograph-
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TIMI Risk Index in NSTEMI April 18, 2006:1553–8cs, practice patterns, and health outcome among patients
ith MI in the U.S. Patient data from NRMI 3 (1,553
ospitals, April 1998 to June 2000) and NRMI 4 (1,272
ospitals, July 2000 to October 2002) were included. Over-
ll mortality was 10.9% and 10.8% in NRMI 3 and 4,
espectively, and all analyses were conducted on the com-
ined dataset. All management decisions were at the dis-
retion of the treating physician. Patients with ST-segment
levation or presumed new left bundle branch block (LBBB)
ere identified as presenting with STEMI and classified
nto those managed with and without early reperfusion
herapy. Patents with MI but without ST-segment elevation
r new LBBB were considered to have NSTEMI. Patients
ith complete data and a heart rate between 50 and 150
eats/min were included as in the derivation of the index (1).
The TRI was calculated using the equation: [heart rate
age/10)2/systolic pressure] (1). This index was initially de-
ived from 12,353 patients enrolled in the Intravenous nPA for
reatment of Infarcting Myocardium Early (InTIME II-
IMI 17) trial (21), a randomized trial of lanoteplase versus
lteplase as reperfusion therapy for STEMI. A significant
raded relationship of the TRI with mortality at 24 h and at
0 days was observed and independently validated in pa-
ients with STEMI from the Thrombolysis In Myocardial
nfarction (TIMI) 9A and 9B trials (1). Because of the
roader spectrum of age and blood pressure observed in a
ommunity-based population compared to selected patients
nrolled in clinical trials, application of the TRI was then
pdated to use 10-point intervals for simple clinical reference
cross a greater range (9). The same 10-point intervals were
sed in the present analysis, which compared patients with
STEMI and those with STEMI enrolled in NRMI.
omparisons were made between NSTEMI and patients
ith STEMI. The patients with STEMI are divided into
wo separate groups, those who received early reperfusion
nd those who did not, as in previous work from this dataset
9). Main comparisons are made between patients with
STEMI and these two groups of patients with STEMI.
ormal comparison of the two STEMI groups has been
reviously published (9).
The prognostic discriminatory capacity of the TRI was
Abbreviations and Acronyms
CHF  congestive heart failure
IQR  interquartile range
LBBB  left bundle branch block
LV  left ventricle/ventricular
MI  myocardial infarction
NRMI  National Registry of Myocardial Infarction
NSTEMI  non–ST-segment elevation myocardial
infarction
STEMI  ST-segment elevation myocardial infarction
TIMI  Thrombolysis In Myocardial Infarction
TRI  Thrombolysis In Myocardial Infarction risk
indexxpressed as the c-statistic, representing the area under the eceiver operator curve for prediction of in-hospital death
22). Differences in event rates across risk index ranges were
ssessed using the chi-square test for trend. For the measure
f general association, a chi-square test was used. Two-
ailed p values 0.05 were considered significant. Statistical
nalyses were performed using SAS 8.02 (SAS Institute,
ary, North Carolina).
ESULTS
erformance of the TRI in NSTEMI. The analysis in-
luded a total of 490,678 patients; 337,192 with NSTEMI and
53,486 with STEMI (81,679 treated with reperfusion
herapy). A strong graded relationship with in-hospital
ortality (1.0% to 34.4%, p  0.001) was evident among
atients with NSTEMI when stratified by the TRI (Fig. 1).
lthough somewhat lower than in the STEMI patients in
hich it was derived, the majority of the discriminative
apacity of the risk index in STEMI was retained in patients
ith NSTEMI (c-statistic  0.73).
aseline characteristics. When compared to patients with
TEMI receiving reperfusion therapy, patients with
STEMI were older (mean 71.9 vs. 62.5, p 0.001), more
ften women (45.0 vs. 31.5), had higher rates of diabetes
ellitus, were less likely to smoke, more likely to have had
history of hypertension, renal failure, and a history of
ongestive heart failure (CHF), MI, or coronary artery
ypass grafting (Table 1). On the other hand, the baseline
haracteristics of patients with NSTEMI were more similar
o those with STEMI who did not receive reperfusion
herapy (Table 1). For example, 24% of the subjects with
STEMI or with STEMI not receiving reperfusion had
prior history of CHF, compared to 4% of subjects with
TEMI who did receive reperfusion therapy. A small
roportion of patients with NSTEMI received immediate
eperfusion therapy in this analysis (6.3%). These patients
lso exhibited a strong graded relationship of TRI with
ortality.
RI profile. The distribution of TRI values by 10-point
ntervals is shown in Figure 2. The distributions of TRI
cores (i.e., the TRI profile) (Fig. 2) was similar in patients
ith NSTEMI (median TRI 32, interquartile range [IQR]
1.1 to 45.6) and patients with STEMI not receiving
eperfusion therapy (median 36.1, IQR 24.5 to 50.0). In
ontrast, patients with STEMI who received early reperfu-
ion therapy had a lower risk profile (median 21.1, IQR 14.7
o 30.3, p  0.001). The percentage of subjects with
STEMI (10.3%) that were at high risk with TRI60 was
imilar to the 14.1% of STEMI subjects without reperfusion
herapy, in contrast to the very small percentage of STEMI
atients receiving reperfusion therapy that were at high risk
2.1%, p  0.001). Among NSTEMI patients, those with
igher risk index values by definition were older, had higher
eart rates, and lower blood pressures. In addition to these
eatures, they are more often women, lighter, Killip classI, less frequently smokers, and have more frequent comor-
b
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April 18, 2006:1553–8 TIMI Risk Index in NSTEMIidities including CHF, chronic obstructive pulmonary
isease, and renal failure (Table 2).
ortality results and index performance. Overall mortal-
ty in the patients with NSTEMI (10.9%) was significantly
igher than among patients with STEMI treated with
ontemporary reperfusion therapy (6.6%), but lower than
he patients with STEMI not receiving reperfusion (18.7%)
Fig. 1B, inset). In low-risk patients (TRI 30), represent-
ng 46% of the NSTEMI patients and 57% of the STEMI
atients, the mortalities were similar. However, in patients
t intermediate or high risk (TRI 30), the NSTEMI
ortality was lower than STEMI with or without reperfu-
ion therapy.
entricular function and risk index. Left ventricular (LV)
unction was determined in 230,267 (68%) of patients in the
ataset with NSTEMI and reported in a binary fashion
40% or40%). Patients who had higher risk index values
ere less likely to have an LV function measure reported.
mong those with TRI 80, only 51% reported a measure
f LV function, compared to 76% of patients with TRI 0 to
10. Among those who did have LV function measured
nd reported, when stratified by TRI values there was an
ncreasing likelihood of having LV function 40% with
igure 1. (A) Relationship between Thrombolysis In Myocardial Infarcti
NSTEMI) (line smoothed to fit data). (B) Relationship between TIM
STEMI. Inset graph shows mortality in full group by diagnosis. HR ncreasing TIMI risk index (Fig. 3, ptrend  0.001) with a pange of 10% (TRI 0 to 10) to 48% (TRI 70 to 80) of
ubjects.
ISCUSSION
his analysis demonstrates that a simple risk index calcu-
ated from age, systolic blood pressure, and heart rate
erived from and validated in STEMI (1,9) is also strongly
ssociated with in-hospital mortality in a nationally repre-
entative sample of 337,192 patients with NSTEMI. It
ight have been anticipated that an early risk index devel-
ped for STEMI would not perform well in predicting early
ortality in NSTEMI, which is not considered to cause the
ame levels of myocardial dysfunction, hemodynamic com-
romise, or serious arrhythmias as STEMI. However, the
redictive capacity of the TRI for short-term mortality in
atients with NSTEMI was similar to that for patients with
TEMI. Despite the differences in pathophysiology and
reatment of patients with STEMI and NSTEMI, the three
omponents of the risk index have a bearing on ultimate
utcome in both conditions. These findings are consistent
ith a previous single-center study showing the utility of the
RI across the spectrum of ACS (23). Moreover, the TRI
IMI) risk index and mortality in non–ST-segment myocardial infarction
k index and mortality in ST-segment myocardial infarction (STEMI),
t rate; RT  reperfusion therapy; SBP  systolic blood pressure.on (Trovides a tool to identify patients with NSTEMI at high
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TIMI Risk Index in NSTEMI April 18, 2006:1553–8isk who may warrant intensive monitoring and care similar
o that given to patients with STEMI.
This analysis demonstrates the relatively high overall
ortality risk of patients presenting with NSTEMI to
ospitals in the U.S. This high risk relates largely to the
igh baseline risk profile of the population. Patients with
STEMI in NRMI, as in previous data sets, are more likely
o be women, and more likely to have significant medical
omorbidities than are patients with STEMI (12,17,24).
Table 1. Baseline Characteristics
Characteristics
NSTE
(n  33
Age, yrs 71.9 
65 (%) 71.
75 (%) 48.
Female gender (%) 45.
Weight, kg 77.8 
Smoker 19.
DM 33.
HTN 62.
Renal failure 13.
History of CHF 24.
History of COPD 18.
History of CVA 12.
MI 28.
Angina 14.
PCI 11.
CABG 16.
Killip class 1 30.
Heart rate, beats/min 90.2 
SBP, mm Hg 146.3 
TIMI risk score (STEMI) median
(25th, 75th percentile)
NA
TRI median
(25th, 75th percentile)
32.0 (21.1
CABG coronary artery bypass grafting; CHF congestive h
cerebrovascular accident; DM diabetes mellitus; HTN hype
elevation MI; PCI  percutaneous coronary intervention; RT
ST-segment elevation MI; TIMIThrombolysis In Myocardiaigure 2. Distribution of Thrombolysis In Myocardial Infarction risk index
on–ST-segment myocardial infarction (NSTEMI). RT  early reperfusion thhese findings primarily reflect differences between the
STEMI patients and those STEMI patients treated with
arly reperfusion therapy. These attributes may in part
xplain the increased total mortality in these patients
10.9%) compared to the patients with STEMI receiving
eperfusion therapy (6.6%). Nevertheless, the TRI retains a
ood ability to stratify risk in such patients with NSTEMI
ithout direct measurement of these comorbid factors, in
art because age correlates well with comorbidities and is an
)
STEMI RT
(n  81,679)
STEMI No RT
(n  71,807)
62.5  13.4 73.6  13.9
43.4 75.2
21.2 53.7
31.5 48.8
83.5  19.5 75.1  20.3
38.2 19.1
20.1 33.1
49.3 60.4
2.6 12.0
4.4 24.4
8.6 16.2
4.5 14.4
17.0 26.6
8.3 12.2
11.8 8.2
6.8 13.2
10.7 35.8
80  18.6 92.5  22.0
141.3  30.1 141.2  33
2.0 (1, 4) 5 (3, 6)
) 21.1 (14.7, 30.3) 36.1 (24.5, 50.0)
lure; COPD chronic obstructive pulmonary disease; CVA
n; MImyocardial infarction; NSTEMI non–ST-segment
erfusion therapy; SBP  systolic blood pressure; STEMI 
tion; TRIThrombolysis In Myocardial Infarction risk index.MI
7,192
13.9
0
4
0
21.0
8
5
4
4
0
0
9
3
2
3
8
8
21.6
32.6
, 45.6
eart fai
rtensioin patients with ST-segment myocardial infarction (STEMI) versus
erapy.
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April 18, 2006:1553–8 TIMI Risk Index in NSTEMImportant component of the TRI. Our previous work
uggests that the TRI contributes independent information
hen considered along with these comorbid factors (1).
Also, it is likely that patients with NSTEMI who exhibit
emodynamic disturbance (i.e., decreased systolic pressure
nd/or increased heart rate) may have limited myocardial
eserve, multivessel coronary artery disease, or additional
omorbidities that result in an impaired ability to tolerate
yocardial ischemia. This is supported by the correlation of
igher risk index values with lower LV ejection fraction (at
east on a population basis). Recognition that a patient with
I and a high TRI is at high risk for mortality regardless of
hether the presenting electrocardiogram exhibits ST-
egment elevation or not may help in the development of
trategies and interventions.
Table 2. Baseline Demographic Risk By Risk
Characteristics
<30
(n  153,590)
Age, yrs 61.7  12.1
65 (%) 41.4
75 (%) 15.3
Female gender (%) 35.4
Weight, kg 85.5  21.3
Smoker 31.3
DM 32.4
HTN 61.4
Renal failure 9.6
History of CHF 12.5
History of COPD 12.3
History of CVA 8.4
MI 25.6
Angina 13.6
PCI 14.4
CABG 17.7
Killip class 1 16.6
Heart rate, beats/min 80.7  18.0
SBP, mm Hg 157.9  30.3
TRI median
(25th, 75th percentile)
20.2 (14.9, 25.0) 4
Abbreviations as in Table 1.d
igure 3. Relationship of left ventricular (LV) ejection fraction to risk
ndex value. TIMI  Thrombolysis In Myocardial Infarction.Overall, when examined by distribution of risk index,
atients with NSTEMI are quite similar to patients with
TEMI who do not receive reperfusion therapy, and both
f these groups of patients have higher values of the TRI
han those with STEMI who received early reperfusion
herapy (Fig. 2). The combination of a higher-risk profile
han STEMI patients who were reperfused and better
hort-term outcomes than STEMI patients not treated with
arly reperfusion therapy with similar TRI profiles results in
n overall mortality rate for NSTEMI that is intermediate
etween the two groups of patients with STEMI.
tudy limitations. This is an observational study, and
aseline and treatment differences among patients with
TEMI and NSTEMI may exist that were not quantified in
his analysis. In addition, decisions regarding reperfusion
herapy in patients with STEMI were made by treating
hysicians. This may have affected outcomes for patients
nd altered the relationships among the groups studied.
his analysis also does not account for patients who would
ave been included but died before hospitalization. Simi-
arly, this analysis (and the NRMI database) is limited to
n-hospital outcomes, and it is possible that the relationship
etween TRI and outcomes in NSTEMI and STEMI
iffers for long-term outcomes.
Patients were categorized into these analyses by presence
r absence of diagnosis of STEMI; therefore, it is possible
hat the NSTEMI group contains some patients with
nstable angina rather than NSTEMI. It is also possible
hat patients with true posterior STEMI with only precor-
Value
NSTEMI Patients
TRI Category
0–60 >60 Total
148,723) (n  34,879) (n  337,192)
3  8.3 85.7  7.0 71.9  13.9
94.9 99.4 71.0
72.0 93.4 48.4
52.1 57.3 45.0
4  18.4 65.8  16.7 77.8  21.0
11.1 6.4 19.8
36.1 27.2 33.5
64.6 57.4 62.4
16.3 17.4 13.4
32.2 40.2 24.0
22.8 23.1 18.0
16.5 17.8 12.9
31.1 28.6 28.3
15.2 12.6 14.2
9.5 4.7 11.3
17.5 9.9 16.8
41.1 49.8 30.8
0  20.0 112.0  19.7 90.2  21.6
7  29.5 110.4  24.7 146.3  32.6
35.1, 48.3) 70.9 (64.5, 82.1) 32.0 (21.1, 45.6)Index
3
(n 
79.
72.
95.
142.
0.9 (ial ST-segment depressions could be classified as
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TIMI Risk Index in NSTEMI April 18, 2006:1553–8STEMI. Because NRMI enrollment requires both sug-
estive presentation and clinical evidence of MI (electrocar-
iogram, enzymes, scintigraphy, or autopsy) and a discharge
iagnosis of MI, we believe the contribution of these two
roups is likely to be small. It is also worth noting that for
STEMI, as with STEMI, the risk index provides an initial
ssessment of risk that should be updated as the patient’s
ourse progresses and more information becomes available.
onclusions. The TRI, calculated from baseline age, sys-
olic pressure, and heart rate of patients presenting with MI,
as derived from and validated among patients with
TEMI. This index provides prognostic information across
he spectrum of patients with acute MI including patients
ith NSTEMI. Early identification of patients with
STEMI who are at risk of in-hospital mortality may
rovide clinicians with important information for initial
riage and treatment of this growing population of patients
ith acute coronary syndromes.
eprint requests and correspondence: Dr. Stephen D. Wiviott,
IMI Study Group, BWH, Cardiovascular Division, 75 Francis
treet, Boston, Massachusetts 02115. E-mail: swiviott@partners.org.
EFERENCES
1. Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index
for rapid initial triage of patients with ST-elevation myocardial
infarction: an InTIME II substudy. Lancet 2001;358:1571–5.
2. Normand ST, Glickman ME, Sharma RG, McNeil BJ. Using
admission characteristics to predict short-term mortality from myo-
cardial infarction in elderly patients. Results from the Cooperative
Cardiovascular Project. JAMA 1996;275:1322–8.
3. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for
ST-elevation myocardial infarction: a convenient, bedside, clinical
score for risk assessment at presentation: an intravenous nPA for
treatment of infarcting myocardium early II trial substudy. Circulation
2000;102:2031–7.
4. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality
in the era of reperfusion for acute myocardial infarction. Results from
an international trial of 41,021 patients. GUSTO-I investigators.
Circulation 1995;91:1659–68.
5. Krumholz HM, Chen J, Chen YT, Wang Y, Radford MJ. Predicting
one-year mortality among elderly survivors of hospitalization for an
acute myocardial infarction: results from the Cooperative Cardiovas-
cular Project. J Am Coll Cardiol 2001;38:453–9.
6. Jacobs DR Jr., Kroenke C, Crow R, et al. PREDICT: a simple risk
score for clinical severity and long-term prognosis after hospitalization
for acute myocardial infarction or unstable angina: the Minnesota
heart survey. Circulation 1999;100:599–607.
7. Hillis LD, Forman S, Braunwald E. Risk stratification before throm-
bolytic therapy in patients with acute myocardial infarction. The
Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-
Investigators. J Am Coll Cardiol 1990;16:313–5.
8. Forrester JS, Diamond GA, Swan HJ. Correlative classification of
clinical and hemodynamic function after acute myocardial infarction.
Am J Cardiol 1977;39:137–45.9. Wiviott SD, Morrow DA, Frederick P, et al. Performance of the
Thrombolysis in Myocardial Infarction risk index in the National
Registry of Myocardial Infarction-3 and -4. A simple index that
predicts mortality in ST-elevation myocardial infarction. J Am Coll
Cardiol 2004;44:783–9.
0. Ryan TJ. The thrombolysis in myocardial infarction risk index: a
formula with a future. J Am Coll Cardiol 2004;44:790–2.
1. Becker RC, Burns M, Every N, et al. Early clinical outcomes and
routine management of patients with non–ST-segment elevation
myocardial infarction: a nationwide perspective. Arch Intern Med
2001;161:601–7.
2. Nicod P, Gilpin E, Dittrich H, et al. Short- and long-term clinical
outcome after Q wave and non–Q wave myocardial infarction in a
large patient population. Circulation 1989;79:528–36.
3. Nyman I, Areskog M, Areskog NH, Swahn E, Wallentin L. Very
early risk stratification by electrocardiogram at rest in men with
suspected unstable coronary heart disease. The RISC Study Group.
J Intern Med 1993;234:293–301.
4. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the
admission electrocardiogram in acute coronary syndromes. JAMA
1999;281:707–13.
5. Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the
characteristics, treatments and outcomes of patients with acute coro-
nary syndromes in Europe and the Mediterranean basin: the Euro
Heart Survey of Acute Coronary Syndromes (Euro Heart Survey
ACS). Eur Heart J 2002;23:1190–201.
6. Roe MT, Parsons LS, Pollack CV Jr., et al. Quality of care by
classification of myocardial infarction: treatment patterns for ST-
segment elevation vs non–ST-segment elevation myocardial infarction.
Arch Intern Med 2005;165:1630–6.
7. Steg PG, Goldberg RJ, Gore JM, et al. Baseline characteristics,
management practices, and in-hospital outcomes of patients hos-
pitalized with acute coronary syndromes in the Global Registry
of Acute Coronary Events (GRACE). Am J Cardiol 2002;90:
358 – 63.
8. Morrow DA, Antman EM, Murphy SA, et al. The risk score profile:
a novel approach to characterising the risk of populations enrolled in
clinical studies. Eur Heart J 2004;25:1139–45.
9. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the
treatment of over 1.5 million patients with myocardial infarction in the
U.S. from 1990 through 1999: the National Registry of Myocardial
Infarction-1, -2 and -3. J Am Coll Cardiol 2000;36:2056–63.
0. Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial
infarction in the United States (1990 to 1993). Observations from the
National Registry of Myocardial Infarction. Circulation 1994;90:
2103–14.
1. InTIME-II Study Investigators. Intravenous NPA for the treatment
of infarcting myocardium early: InTIME-II, a double-blind compar-
ison of single-bolus lanoteplase vs accelerated alteplase for the treat-
ment of patients with acute myocardial infarction. Eur Heart J
2000;21:2005–13.
2. Hanley JA, McNeil BJ. The meaning and use of the area under a
receiver operating characteristic (ROC) curve. Radiology 1982;143:
29–36.
3. Ilkjanoff L, O’Donnell CJ, Camargo CA, O’Halloran TD, Giugliano
RP, Lloyd-Jones DM. The TIMI risk index predicts in-hospital
mortality across the spectrum of acute coronary syndromes. Am J
Cardiol 2005;96:773–7.
4. Rouleau JL, Talajic M, Sussex B, et al. Myocardial infarction patients
in the 1990s—their risk factors, stratification and survival in Canada:
the Canadian Assessment of Myocardial Infarction (CAMI) study.
J Am Coll Cardiol 1996;27:1119–27.
